title: The cycle characteristics of clomiphene with clomiphene and menotropins in polycystic ovary syndrome and non polycystic ovary syndrome infertile patients.
abstract: OBJECTIVE
  This study compares the cycle characteristics of clomiphene (CC) with CC+HMG (Human Menopausal Gonadotropin or Menotropins) in Polycystic Ovary Syndrome (PCOS) and non-PCOS infertile patients.
  
  
  METHODS
  Patients were treated by CC + minimal HMg protocol. The cancellation rate, the mean number of different follicle sizes and endometrial thickness and pattern were compared.
  
  
  RESULTS
  The cancelled cycles due to non-responsiveness were significantly higher in CC compared to CC+ minimal HMg protocol. PCOS patients are significantly nonresponsive in CC cycle and hyperresponsive in CC+ minimal HMg cycles. The mean number of different sizes of follicles and the endometrial thickness were significantly higher in CC+ minimal HMg. PCOS patients were significantly different from non-PCOS regarding the number of mature follicle and endometrial thickness. The pregnancy rate was 11% (10.2% in non-PCOS and 12.2% in PCOS).
  
  
  CONCLUSIONS
  CC+ minimal HMg is a viable alternative to HMg /FSH only protocol in CC failure or resistant patients, and its efficacy can be mostly attributed to improvement of endometrial quality and increase in follicle number. Moreover, due to high cancellation of PCOS patients treated by this protocol, seemingly other alternatives should be found; perhaps sequential letrozole+HMg/FSH that have been shown to improve the ovarian response in this group of patients.
authors.affiliation: Department of Gynecology and Obstetrics, Faculty of Medicine, Zahedan University of Medical Sciences Zahedan, Iran.
authors.forename: M
authors.initials: M
authors.lastname: Ghasemi
authors.forename: H
authors.initials: H
authors.lastname: Ashraf
authors.forename: H
authors.initials: H
authors.lastname: Koushyar
authors.forename: N
authors.initials: N
authors.lastname: Mousavifar
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D002996:Clomiphene / Q000627:therapeutic use*; D004351:Drug Resistance; D004717:Endometrium / Q000187:drug effects / Q000378:metabolism; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy*; D008596:Menotropins / Q000627:therapeutic use*; D006080:Ovarian Follicle / Q000187:drug effects / Q000378:metabolism; D011085:Polycystic Ovary Syndrome / Q000150:complications; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D017211:Treatment Failure; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D005300:Fertility Agents, Female; D002996:Clomiphene; D008596:Menotropins